<!DOCTYPE html>
<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/
-->
<!--[if lt IE 7]>
<html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en">
<![endif]-->
<!--[if IE 7]>
<html class="no-js lt-ie9 lt-ie8" lang="en">
<![endif]-->
<!--[if IE 8]>
<html class="no-js lt-ie9" lang="en">
<![endif]-->
<!--[if gt IE 8]>
<!-->
<html class="no-js" lang="en">
<!--<![endif]-->

<head>
    <meta charset="utf-8" />
    <!-- Set the viewport width to device width for mobile -->
    <meta name="viewport" content="width=device-width" />
    <title>
        PracticeUpdate : Expert Opinion Item
    </title>
    <link rel="stylesheet" href="assets/css/app.css">
    <link rel="stylesheet" href="assets/css/font-awesome.css">
    <link rel="stylesheet" href="assets/css/fc-webicons.css">
    <link rel="stylesheet" href="assets/css/foundation-icons-general.css">
    <script src="assets/js/foundation/modernizr.foundation.js">
    </script>
    <!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js">
        </script>
    <![endif]-->
</head>

<body id="page" class="update off-canvas slide-nav expert-opinion-item logged-out">
    <div class="widget ad">
        <div id="leaderboard" class="Breast ad-container">
            <div class="ad-title">
                <span class="ad-title-text">
                    advertisement
                </span>
            </div>
            <!--/.ad-title-->
            <div id="leaderboardcontent" class="ad-content">
            </div>
            <!--.ad-content-->
        </div>
        <!--/#leaderboard.ad-container-->
    </div>
    <!--/.widget.ad-->
    <div class="page-header">
    </div>
    <!--/.page-header-->
    <div class="page-content">
        <section role="main">
            <div class="single-item-container">
                <article class="type-expert-opinion single-item">
                    <!-- info taken from: http://oncologystat.com/viewpoints/seminal_articles/Seminal_Articles_Germ_Cell_Tumors.html
                    -->
                    <div class="item-header-container">
                        <header class="item-header">
                            <div class="flag-container">
                                <span class="flag featured">
                                    <i class="icon-bolt">
                                    </i>
                                    featured
                                </span>
                                <span class="flag story-of-the-week">
                                    <i class="icon-bolt">
                                    </i>
                                    story of the week
                                </span>
                            </div>
                            <div class="meta pub-meta">
                                <span class="item-type">
                                    Seminal Article
                                </span>
                                <span class="item-pub-date">
                                    <time datetime="12-12-19">
                                        December 19, 2012
                                </span>
                            </div>
                            <hgroup class="item-title-container">
                                <h1 class="item-title">
                                    Seminal Articles—Leukemia
                                </h1>
                                <p class="item-citation">
                                    <!-- {{source.citation}} -->
                                    2012 Aug 28, Isabel Cunningham, MD, Editor: Eytan Stein, MD
                                </p>
                            </hgroup>
                            <!-- /.item-title-container -->
                        </header>
                    </div>
                    <!--/.item-header-container-->
                    <div class="item-content-container">
                        <div class="item-content">
                            <div class="item-content-section">
                                <section class="seminal-article-body">
                                    <div class="seminal-article-body-container">
                                        <div class="source-container">
                                            <div class="vcard">
                                            </div>
                                            <!--/.vcard-->
                                        </div>
                                        <!--/.source-container-->
                                        <p>Based on our expert's review, here are the must-read articles for every oncologist about patients with leukemia.</p><p><strong>Acute Myeloid Leukemia &ndash; Prognosis</strong></p><p>1. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1112304">N Engl J Med. 2012;366(12):1079&ndash;1089</a>.</p><p><strong>Acute Myeloid Leukemia &ndash; Treatment</strong></p><p>2. Preisler H, Davis RB, Kirshner J, et al. Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study. <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/69/5/1441.full.pdf+html">Blood. 1987;69(5):1441&ndash;1449</a>. <strong>Free</strong></p><p>3. Mandelli F, Vignetti M, Suciu S, et al. Daunorubicin versus mitoxantrone versus idarubicin as induction and consolidation chemotherapy for adults with acute myeloid leukemia: the EORTC and GIMEMA Groups Study AML-10. <a target="_blank" href="http://jco.ascopubs.org/content/27/32/5397.abstract?sid=a07068dc-2e32-486f-ae5c-6fe04145eef5">J Clin Oncol. 2009;27(32):5397&ndash;5403</a>.</p><p>4. Löwenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1010222">N Engl J Med. 2011;364(11):1027&ndash;1036</a>. <strong>Free</strong></p><p>5. Löwenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa0901409">N Engl J Med. 2009;361(13):1235&ndash;1248</a>. <strong>Free</strong></p><p>6. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJM199410063311402">New Engl J Med. 1994;331(14):896&ndash;903</a>. <strong>Free</strong></p><p>7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. <a target="_blank" href="http://jco.ascopubs.org/content/28/4/562.abstract?sid=7402404f-4a7b-4c12-b64c-54ccd65f8fa9">J Clin Oncol. 2010;28(4):562&ndash;569</a>.</p><p>8. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. <a target="_blank" href="http://onlinelibrary.wiley.com/doi/10.1002/cncr.22496/pdf">Cancer. 2007;109(6):1114&ndash;1124</a>. <strong>Free</strong></p><p>9. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trial. <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/116/3/354.full.pdf+html">Blood. 2010;116(3):354&ndash;365</a>. <strong>Free</strong></p><p>10. Berman E, Wiernik P, Volger R, et al. Long-term follow-up of three randomized trials comparing idarubicin and daunorubicin as induction therapies for patients with untreated acute myeloid leukemia. <a target="_blank" href="http://onlinelibrary.wiley.com/doi/10.1002/%28SICI%291097-0142%2819971201%2980:11%2B%3C2181::AID-CNCR3%3E3.0.CO;2-L/pdf">Cancer. 1997;80(11 Suppl):2181&ndash;2185</a>. <strong>Free</strong></p><p><strong>Acute Promyelocytic Leukemia</strong></p><p>11. Powell B, Moser B, Stock W, et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/116/19/3751.full.pdf+html">Blood. 2010;116(19):3751&ndash;3757</a>. <strong>Free</strong></p><p>12. Lo-Coco F, Avvisati, Vignetti M, et al. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/116/17/3171.full.pdf+html">Blood. 2010;116(17):3171&ndash;3179</a>. <strong>Free</strong></p><p>13. Sanz MA, Montesinos P, Rayón C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/115/25/5137.full.pdf+html">Blood.2010;115(25):5137&ndash;5146</a>. <strong>Free</strong></p><p>14. Lengfelder E, Hofmann WK, Nowak D. Impact of arsenic trioxide in the treatment of acute promyelocytic leukemia. <a target="_blank" href="http://www.nature.com/leu/journal/v26/n3/full/leu2011245a.html">Leukemia. 2012;26(3):433&ndash;442</a>.</p><p><strong>Acute Lymphocytic Leukemia</strong></p><p>15. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. <a target="_blank" href="http://jco.ascopubs.org/content/18/3/547.abstract?sid=b6ccc182-fede-445c-9e3d-2bb563b7d144">J Clin Oncol. 2000;18(3):547&ndash;561</a>.</p><p>16. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/106/12/3760.full.pdf+html">Blood. 2005;106(12):3760&ndash;3767</a>. <strong>Free</strong></p><p>17. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/111/4/1827.full.pdf+html">Blood. 2008;111(4):1827&ndash;1833</a>. <strong>Free</strong></p><p>18. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/116/12/2070.full.pdf+html">Blood. 2010;116(12):2070&ndash;2077</a>. <strong>Free</strong></p><p>19. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. <a target="_blank" href="http://jco.ascopubs.org/content/29/5/532.abstract?sid=d6dcdb9b-82d8-43b4-b87e-27dd92037099">J Clin Oncol. 2011;29(5):532&ndash;543</a>.</p><p>20. Patel B, Rai L, Buck G, et al. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993. <a target="_blank" href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2009.07941.x/pdf">Br J Haematol. 2010;148(1):80&ndash;89</a>. <strong>Free</strong></p><p>21. Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/114/25/5136.full.pdf+html">Blood. 2009;114(25):5136&ndash;5145</a>. <strong>Free</strong></p><p>22. Ravandi F. Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors. <a target="_blank" href="http://cigjournals.metapress.com/content/3nm762035751489q/">Clin Lymphoma Myeloma Leuk. 2011;11(2):198&ndash;203</a>.</p><p><strong>Chronic Myeloid Leukemia</strong></p><p>23. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa022457">N Engl J Med. 2003;348(11):994&ndash;1004</a>. <strong>Free</strong></p><p>24. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1002315">N Engl J Med. 2010;362(24):2260&ndash;2270</a>. <strong>Free</strong></p><p>25. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa0912614">N Engl J Med. 2010;362(24):2251&ndash;2259</a>. <strong>Free</strong></p><p>26. Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. <a target="_blank" href="http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2811%2970201-7/abstract">Lancet Oncol. 2011;12(9):841&ndash;851</a>.</p><p>27. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa1004095">N Engl J Med. 2010;363(26):2511&ndash;2521</a>. <strong>Free</strong></p><p>28. Branford S, Hughes TP. Mutational analysis in chronic myeloid leukemia: when and what to do? <a target="_blank" href="http://journals.lww.com/co-hematology/Abstract/2011/03000/Mutational_analysis_in_chronic_myeloid_leukemia_.8.aspx">Current Opin Hematol. 2011;18(2):111&ndash;116</a>.</p><p><strong>Chronic Lymphocytic Leukemia &ndash; Prognosis</strong></p><p>29. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. <a target="_blank" href="http://bloodjournal.hematologylibrary.org/content/46/2/219.full.pdf+html">Blood. 1975;46(2):219&ndash;234</a>. <strong>Free</strong></p><p>30. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJM200012283432602">New Engl J Med. 2000;343(26):1910&ndash;1916</a>. <strong>Free</strong></p><p>31. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJMoa040857">New Engl J Med. 2004;351(9):893&ndash;901</a>. <strong>Free</strong></p><p><strong>Chronic Lymphocytic Leukemia &ndash; Treatment</strong></p><p>32. Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. <a target="_blank" href="http://www.nejm.org/doi/full/10.1056/NEJM200012143432402">N Engl J Med. 2000;343(24):1750&ndash;1757</a>. <strong>Free</strong></p><p>33. Catovsky D, Richards S, Matutes E, et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. <a target="_blank" href="http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961125-8/abstract">Lancet. 2007;370(9583):230&ndash;239</a>.</p><p>34. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. <a target="_blank" href="http://jco.ascopubs.org/content/28/10/1756.abstract?sid=bda15ff4-93be-400b-bd9a-febcbecaae50">J Clin Oncol. 2010;28(10):1756&ndash;1765</a>.</p><p>35. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. <a target="_blank" href="http://www.sciencedirect.com/science/article/pii/S0140673610613815">Lancet. 2010;376(9747):1164&ndash;1174</a>.</p><p>36. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. <a target="_blank" href="http://www.sciencedirect.com/science/article/pii/S147020451170242X">Lancet Oncol. 2011;12(13):1204&ndash;1213</a>.</p><p>37. Böttcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. <a target="_blank" href="http://jco.ascopubs.org/content/30/9/980.abstract?sid=80449889-acea-4690-82a1-cd1539c9e009">J Clin Oncol. 2012;30(9):980&ndash;988</a>.</p><p>38. Cramer P, Hallek M. Prognostic factors in chronic lymphocytic leukemia-what do we need to know? <a target="_blank" href="http://www.hematologylibrary.org/site/webfocus/content/4-nat_rev-cramer.pdf">Nat Rev Clin Oncol. 2011;8(1):38&ndash;47</a>.</p><p></p>
                                    </div>
                                    <!--/.seminal-article-body-container -->
                                </section>
                                <!-- /.seminal-article-body -->
                            </div>
                            <!-- ./item-content-section -->
                        </div>
                        <!-- ./item-content -->
                    </div>
                    <!-- /.item-conten-container -->
                    <hr />
                    <footer class="copyright item-footer">
                        <img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"
                        />
                        <p>
                            Copyright &copy; 2012 Elsevier
                        </p>
                    </footer>
            </div>
            <!--/.item-container-->
            <div class="recommended">
                <div class="recent">
                </div>
                <!--/.recent-->
                <div class="ad">
                    <img src="http://placehold.it/300x250" align="ad" title="ad" />
                </div>
            </div>
            <!--/.recommended-->
        </section>
        <!--/[role="main"]-->
        <section id="sidebar" role="complementary">
            <div class="dashboard">
                <div class="panel cta register">
                    <p>
                        <!-- Meet Our Experts -->
                        Become a member to customize this page.
                        <p>
                            <a class="button" href="#action-register">Register for free</a>
                </div>
                <!--/.panel.cta.register-->
                <div class="component user-console">
                </div>
                <!--/.component.user-console-->
                <div class="component user-topic">
                </div>
                <!--/.component.user-topic-->
                <div class="component topic-spotlight">
                </div>
                <!--/.component.topic-spotlight-->
                <div class="panel">
                    <img src="http://placehold.it/200x200" />
                    <p>
                        <!-- Meet Our Experts -->
                        Meet our Advisory and Editorial Boards comprised of physician editors
                        and world-renowned experts.
                        <p>
                </div>
            </div>
            <!--/.sidebar-->
        </section>
        <!--/.[role="complimentary"]-->
    </div>
    <!--/.page-content-->
	<div class="page-footer-container">
    <footer class="page-footer">
    </footer>
	</div><!-- /.page-footer-container -->
    <!-- /.page-footer -->
    <!-- Included JS Files (Uncompressed) -->
    <script src="assets/js/foundation/jquery.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.accordion.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.alerts.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.buttons.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.forms.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.navigation.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.orbit.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.reveal.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tabs.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tooltips.js">
    </script>
    <script src="assets/js/foundation/jquery.placeholder.js">
    </script>
    <script src="assets/js/foundation/app.js">
    </script>
    <script src="assets/js/foundation/jquery.offcanvas.js">
    </script>
    <script src="assets/js/mustache.js">
    </script>
    <!-- Mustache - homepage feed template -->
    <script>
                    	<!--
	Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
	    $.get('assets/mustache/feed-item.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.stream-container').html(html);
	    });

	});

	<!--
	Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
	    $.get('assets/mustache/recent.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.recent').html(html);
	    });

	});

	<!--
	Mustache - homepage user - console template -->
	$.getJSON('content/json/user-console.json', function(data) {
	    $.get('assets/mustache/user-console.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-console').html(html);
	    });
	});

	<!--
	Mustache - homepage user - topic template -->
	$.getJSON('content/json/user-topic.json', function(data) {
	    $.get('assets/mustache/user-topic.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-topic').html(html);
	    });
	});

	<!--
	Mustache - homepage topic - spotlight template -->
	$.getJSON('content/json/topic-spotlight.json', function(data) {
	    $.get('assets/mustache/topic-spotlight.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.topic-spotlight').html(html);
	    });
	});
</script>
</body>

</html>